Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasisulam in 3rd-line Metastatic NSCLC
NCT00363766Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2006
- Primary completion
- Oct 2008
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tasisulam, sponsored by Eli Lilly and Company. Primary endpoint: Time to Progression up to 10.35 months. Started Sep 2006; status: completed.
02
Drugs
tasisulam
Beyond the preview
Go deeper on NCT00363766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363766.